ClinicalTrials.gg
CompletedNCT01010750Updated Jun 14, 2021Results posted

Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

A Phase 1 interventional study of Lisdexamfetamine Dimesylate (LDX) and Immediate Release Mixed Amphetamine Salts (MAS-IR) in Attention-Deficit Hyperactivity Disorder, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
46th of 51
18 · median 48
Started
2010
with 4 others
Phase 1
2 of 51
none open now
Registered
23rd of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 46th largest by enrollment, is one of 5 that started in 2010, is one of 2 in phase 1, and was the 23rd registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

To evaluate the sensitivity and responsiveness of a standardized, validated, computer-based, battery of neuro-psychometric tests in adults with ADHD.

03

Conditions studied

  • Attention-Deficit Hyperactivity Disorder

Keywords

  • ADHD
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Subject meets Fourth Edition; Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD (diagnostic code 314.00 and 314.01) established by a comprehensive psychiatric evaluation that reviews DSM-IV-TR criteria with at least 6 of the 9 subtype criteria met.
  2. Subject has been previously treated for ADHD with an adequate course of amphetamine therapy with no history of intolerance, or lack of efficacy, as determined by the Investigator.
  3. Subject does not have any physical disability (eg. colorblindness, limitations with use of one or both hands, etc) that would interfere with the subject's participation in or performance on any of the neuropsychometric tests. For a number of these tasks speed is a key factor thus subjects cannot have any obvious impediments/impairments in the use of their hands.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Active comparator
    LDX + MAS-IR Placebo

    Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo

    Drug: Lisdexamfetamine Dimesylate (LDX)

  • Active comparator
    MAS-IR + LDX Placebo

    Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo

    Drug: Immediate Release Mixed Amphetamine Salts (MAS-IR)

  • Placebo comparator
    Placebo

    Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo

    Drug: LDX Placebo + MAS-IR Placebo

Interventions

  • Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo

  • DrugImmediate Release Mixed Amphetamine Salts (MAS-IR)

    Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo

  • DrugLDX Placebo + MAS-IR Placebo

    Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo

06

What researchers measure

Primary outcomes

  1. Power of Attention Score

    The Power of Attention score reflects the ability to focus attention, and is calculated as the sum of the reaction time, measured in milliseconds, from 3 attention tests (Simple Reaction Time, Choice Reaction Time, and Digit Vigilance Speed). Faster performance (lower times) reflects more intense concentration. A decrease in the Power of Attention score indicates improvement.

    Time frame: pre-dose and at 1, 2, 3, 4, 5, 8, 12, 14 and 16 hours post-dose on Day 7

Secondary outcomes

  1. Conners Adult ADHD Rating Scales-Self Report: Short Version (CAARS-S:S) Subscale Total Score (T-Score): Inattention/Memory Problems

    Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

    Time frame: 2 and 14 hours post-dose on Day 7

  2. CAARS-S:S Subscale T-Score: Hyperactivity/Restlessness

    Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

    Time frame: 2 and 14 hours post-dose on Day 7

  3. CAARS-S:S Subscale T-Score: Impulsivity/Emotional Liability

    Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

    Time frame: 2 and 14 hours post-dose on Day 7

  4. CAARS-S:S Subscale T-Score: Problems With Self-Concept

    Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

    Time frame: 2 and 14 hours post-dose on Day 7

  5. CAARS-S:S Subscale T-Score: Attention Deficit Hyperactivity Disorder (ADHD) Index

    Consists of 12 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

    Time frame: 2 and 14 hours post-dose on Day 7

07

Results

Posted Feb 25, 2011

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneLDX 50 mg First, Then MAS-IR 20 mg, Then PlaceboLDX 50 mg First, Then Placebo, Then MAS-IR 20 mgPlacebo First, Then LDX 50 mg, Then MAS-IR 20 mgPlacebo First, Then MAS-IR 20 mg, Then LDX 50 mgMAS-IR 20 mg First, Then LDX 50 mg, Then PlaceboMAS-IR 20 mg First, Then Placebo, Then LDX 50 mg
Started343323
Completed343323
Not completed000000
Second Intervention
Participant flow — Second Intervention
MilestoneLDX 50 mg First, Then MAS-IR 20 mg, Then PlaceboLDX 50 mg First, Then Placebo, Then MAS-IR 20 mgPlacebo First, Then LDX 50 mg, Then MAS-IR 20 mgPlacebo First, Then MAS-IR 20 mg, Then LDX 50 mgMAS-IR 20 mg First, Then LDX 50 mg, Then PlaceboMAS-IR 20 mg First, Then Placebo, Then LDX 50 mg
Started343323
Completed333323
Not completed010000
Withdrew: Adverse event010000
Third Intervention
Participant flow — Third Intervention
MilestoneLDX 50 mg First, Then MAS-IR 20 mg, Then PlaceboLDX 50 mg First, Then Placebo, Then MAS-IR 20 mgPlacebo First, Then LDX 50 mg, Then MAS-IR 20 mgPlacebo First, Then MAS-IR 20 mg, Then LDX 50 mgMAS-IR 20 mg First, Then LDX 50 mg, Then PlaceboMAS-IR 20 mg First, Then Placebo, Then LDX 50 mg
Started333323
Completed333323
Not completed000000

Outcome measures

PrimaryPower of Attention Score

The Power of Attention score reflects the ability to focus attention, and is calculated as the sum of the reaction time, measured in milliseconds, from 3 attention tests (Simple Reaction Time, Choice Reaction Time, and Digit Vigilance Speed). Faster performance (lower times) reflects more intense concentration. A decrease in the Power of Attention score indicates improvement.

Time frame:
pre-dose and at 1, 2, 3, 4, 5, 8, 12, 14 and 16 hours post-dose on Day 7
Reported as:
Mean · milliseconds
Power of Attention Score
millisecondsLDX 50 mgMAS-IR 20 mgPlacebo
half an hour prior to dosing1260.7 ± 34.0001324.1 ± 47.1421272.8 ± 33.729
1 hour post-dose1244.6 ± 32.8871307.4 ± 42.9081253.1 ± 24.174
2 hours post-dose1315.5 ± 67.2461255.0 ± 33.9051296.2 ± 39.808
3 hours post-dose1219.1 ± 33.4281229.6 ± 37.8651301.0 ± 40.864
4 hours post-dose1225.9 ± 40.1921236.5 ± 36.8391275.4 ± 35.302
5 hours post-dose1179.6 ± 35.0221251.4 ± 42.6071330.3 ± 49.623
8 hours post-dose1212.0 ± 36.1131259.3 ± 35.8831304.5 ± 43.802
12 hours post-dose1232.4 ± 48.1831239.3 ± 38.4651262.1 ± 40.795
14 hours post-dose1199.3 ± 35.9471270.1 ± 39.5391270.5 ± 44.814
16 hours post-dose1202.6 ± 37.1351255.9 ± 36.3781270.3 ± 48.581
SecondaryConners Adult ADHD Rating Scales-Self Report: Short Version (CAARS-S:S) Subscale Total Score (T-Score): Inattention/Memory Problems

Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

Time frame:
2 and 14 hours post-dose on Day 7
Reported as:
Mean · Units on a scale
Conners Adult ADHD Rating Scales-Self Report: Short Version (CAARS-S:S) Subscale Total Score (T-Score): Inattention/Memory Problems
Units on a scaleLDX 50 mgMAS-IR 20 mgPlacebo
2 hours post-dose66.16 ± 2.92763.39 ± 3.31964.92 ± 2.775
14 hours post-dose65.78 ± 3.02964.45 ± 2.48366.33 ± 2.398
SecondaryCAARS-S:S Subscale T-Score: Hyperactivity/Restlessness

Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

Time frame:
2 and 14 hours post-dose on Day 7
Reported as:
Mean · Units on a scale
CAARS-S:S Subscale T-Score: Hyperactivity/Restlessness
Units on a scaleLDX 50 mgMAS-IR 20 mgPlacebo
2 hours post-dose64.21 ± 2.99663.62 ± 3.37263.28 ± 3.063
14 hours post-dose65.08 ± 2.83763.41 ± 2.76365.74 ± 2.597
SecondaryCAARS-S:S Subscale T-Score: Impulsivity/Emotional Liability

Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

Time frame:
2 and 14 hours post-dose on Day 7
Reported as:
Mean · Units on a scale
CAARS-S:S Subscale T-Score: Impulsivity/Emotional Liability
Units on a scaleLDX 50 mgMAS-IR 20 mgPlacebo
2 hours post-dose55.46 ± 2.93154.58 ± 3.47054.66 ± 3.421
14 hours post-dose57.82 ± 3.47951.53 ± 2.80255.78 ± 2.773
SecondaryCAARS-S:S Subscale T-Score: Problems With Self-Concept

Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

Time frame:
2 and 14 hours post-dose on Day 7
Reported as:
Mean · Units on a scale
CAARS-S:S Subscale T-Score: Problems With Self-Concept
Units on a scaleLDX 50 mgMAS-IR 20 mgPlacebo
2 hours post-dose58.71 ± 3.53359.78 ± 3.39058.40 ± 3.279
14 hours post-dose59.68 ± 3.84159.54 ± 3.57459.68 ± 3.055
SecondaryCAARS-S:S Subscale T-Score: Attention Deficit Hyperactivity Disorder (ADHD) Index

Consists of 12 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 \* (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50.

Time frame:
2 and 14 hours post-dose on Day 7
Reported as:
Mean · Units on a scale
CAARS-S:S Subscale T-Score: Attention Deficit Hyperactivity Disorder (ADHD) Index
Units on a scaleLDX 50 mgMAS-IR 20 mgPlacebo
2 hours post-dose64.82 ± 3.14763.90 ± 3.76664.59 ± 3.681
14 hours post-dose66.56 ± 3.71463.09 ± 2.94564.85 ± 3.118

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDX 50 mg—0/18 (0%)12/18 (66.7%)
MAS-IR 20 mg—0/17 (0%)9/17 (52.9%)
Placebo—0/17 (0%)8/17 (47.1%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventLDX 50 mgMAS-IR 20 mgPlacebo
Dry MouthGastrointestinal disorders6/184/173/17
Decreased AppetiteMetabolism and nutrition disorders3/184/171/17
HeadacheNervous system disorders1/181/173/17
DyspnoeaRespiratory, thoracic and mediastinal disorders1/182/170/17
Feeling JitteryGeneral disorders1/182/170/17
Heart Rate IncreasedInvestigations2/180/170/17
DizzinessNervous system disorders1/181/171/17
SedationNervous system disorders0/181/170/17
InsomniaPsychiatric disorders1/181/170/17
NervousnessPsychiatric disorders0/181/170/17

Baseline characteristics

Age, Continuous
Age, Continuous(years)LDX 50 mg First, Then MAS-IR 20 mg, Then PlaceboLDX 50 mg First, Then Placebo, Then MAS-IR 20 mgPlacebo First, Them LDX 50 mg, Then MAS-IR 20 mgPlacebo First, Then MAS-IR 20 mg, Then LDX 50 mgMAS-IR 20 mg First, Then LDX 50 mg, Then PlaceboMAS-IR 20 mg First, Then Placebo, Then LDX 50 mgTotal
Mean25.0 ± 1.0024.8 ± 6.7030.3 ± 6.1131.3 ± 11.3753.0 ± 0.0030.0 ± 11.3630.8 ± 10.75
Age, Customized
Age, Customized(Participants)LDX 50 mg First, Then MAS-IR 20 mg, Then PlaceboLDX 50 mg First, Then Placebo, Then MAS-IR 20 mgPlacebo First, Them LDX 50 mg, Then MAS-IR 20 mgPlacebo First, Then MAS-IR 20 mg, Then LDX 50 mgMAS-IR 20 mg First, Then LDX 50 mg, Then PlaceboMAS-IR 20 mg First, Then Placebo, Then LDX 50 mgTotal
<18 years0000000
Between 18 and 55 years34332318
>=56 years0000000
Sex: Female, Male
Sex: Female, Male(Participants)LDX 50 mg First, Then MAS-IR 20 mg, Then PlaceboLDX 50 mg First, Then Placebo, Then MAS-IR 20 mgPlacebo First, Them LDX 50 mg, Then MAS-IR 20 mgPlacebo First, Then MAS-IR 20 mg, Then LDX 50 mgMAS-IR 20 mg First, Then LDX 50 mg, Then PlaceboMAS-IR 20 mg First, Then Placebo, Then LDX 50 mgTotal
Female0211127
Male32221111
Region of Enrollment
Region of Enrollment(Participants)LDX 50 mg First, Then MAS-IR 20 mg, Then PlaceboLDX 50 mg First, Then Placebo, Then MAS-IR 20 mgPlacebo First, Them LDX 50 mg, Then MAS-IR 20 mgPlacebo First, Then MAS-IR 20 mg, Then LDX 50 mgMAS-IR 20 mg First, Then LDX 50 mg, Then PlaceboMAS-IR 20 mg First, Then Placebo, Then LDX 50 mgTotal
United States34332318
08

Study locations

1 site
  • Claghorn-Lesem Research Clinic
    Houston, Texas, United States
09

References and documents

Publications

  • Martin PT, Corcoran M, Zhang P, Katic A. Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder. Clin Drug Investig. 2014 Feb;34(2):147-57. doi: 10.1007/s40261-013-0156-z. PubMed 24297663 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2010 to primary completion in Mar 2010, 2 months.

Results were first posted in Feb 2011, 10 months after primary completion.

Of 21 industry-sponsored phase 1 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 2 months of starting (the median); a quarter within 1 and three quarters within 7. This study's 2 months is close to that.

Counting every sponsor, half of 35 studies reached it within 9 months; a quarter within 2 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2009
First posted
Nov 10, 2009
StartActual
Jan 5, 2010
Primary completionActual
Mar 28, 2010
CompletionActual
Mar 28, 2010
Results first posted
Feb 25, 2011
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01010750
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 10, 2009
Start date
Jan 5, 2010
Primary completion
Mar 28, 2010
Completion
Mar 28, 2010
Results posted
Feb 25, 2011
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion